person · Reporting owner

Gutfreund John Peter

Disclosed activity across 1 company

Tapewire entity: 111691
SEC CIK: 0001940797

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Insight Molecular Diagnostics Inc.

Report date June 30, 2023 · Filed July 03, 2023

Section 16 reporting ended · disclosed 2023-07-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, no par valueSEC Table I · non-derivative	IndirectSee Footnotes	0	Reported balance After 2023-06-30 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2023-06-30 · Other · Disposed 3,085,047 · Balance 0 F1: Represents shares of Common Stock of Oncocyte Corporation (the "Issuer"), no par value (the "Common Stock"), that were distributed by Halle Special Situations Fund LLC (the "Halle Fund") on a pro rata basis to its members (the "Halle Common Stock Distribution"). F2: Represents shares of Common Stock directly beneficially owned by the Halle Fund. John Peter Gutfreund (the "Reporting Person") is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund. F3: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities.
Common Stock, no par valueSEC Table I · non-derivative	IndirectSee Footnotes	3,079,372	Reported balance Holding disclosure · report date 2023-06-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,079,372 F4: Includes 2,004,372 shares of Common Stock received by Newtown Road 130 Holdings LLC ("Newtown") from the Halle Fund as a result of the Halle Common Stock Distribution. The acquisition of the shares of Common Stock by Newtown in the Halle Common Stock Distribution constituted a change in the form of beneficial ownership without a change in pecuniary interest that is exempt from Section 16 of the Exchange Act pursuant to Rule 16a-13 thereunder. Rule 16a-9(a) under the Exchange Act may also exempt the acquisition of the shares of Common Stock by Newtown in the Halle Common Stock Distribution from Section 16 of the Exchange Act. F3: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities. F5: Represents shares of Common Stock directly beneficially owned by Newtown. The Reporting Person is the managing member and a control person of Newtown. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by Newtown.
Common Stock, no par valueSEC Table I · non-derivative	IndirectSee Footnotes	25,000	Reported balance Holding disclosure · report date 2023-06-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 25,000 F3: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities. F6: Represents shares of Common Stock held by or for the benefit of the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities. In such capacity, the Reporting Person may be deemed to beneficially own any securities held by or for the benefit of the minor children of the Reporting Person.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-04-19	IndirectSee Footnotes	0	Reported balance After 2023-06-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-06-30 · Other · Disposed 3,564,728 · Balance 0 F8: Represents warrants to purchase shares of Common Stock (the "Warrants") that were distributed by the Halle Fund on a pro rata basis to its members (the "Halle Warrant Distribution"). F9: The Warrants are currently exercisable, subject to a beneficial ownership limitation of 4.99%. F3: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities. F10: Represents Warrants directly beneficially owned by the Halle Fund. The Reporting Person is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-04-19	IndirectSee Footnotes	992,495	Reported balance Holding disclosure · report date 2023-06-30 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 992,495 F9: The Warrants are currently exercisable, subject to a beneficial ownership limitation of 4.99%. F11: Represents Warrants received by Newtown from the Halle Fund as a result of the Halle Warrant Distribution. The acquisition of the Warrants by Newtown in the Halle Warrant Distribution constituted a change in the form of beneficial ownership without a change in pecuniary interest that is exempt from Section 16 of the Exchange Act pursuant to Rule 16a-13 thereunder. Rule 16a-9(a) under the Exchange Act may also exempt the acquisition of the Warrants by Newtown in the Halle Warrant Distribution from Section 16 of the Exchange Act. F3: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities. F12: Represents Warrants directly beneficially owned by Newtown. The Reporting Person is the managing member and a control person of Newtown. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by Newtown.
Common Stock, no par valueSEC Table I · non-derivative	Direct	715,000	Reported balance Holding disclosure · report date 2023-06-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 715,000 F7: Includes 10,000 restricted stock units, which will vest on August 15, 2023.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2032-08-15	Direct	45,000	Reported balance Holding disclosure · report date 2023-06-30 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 45,000 F13: The options to purchase shares of Common Stock will vest on August 15, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock of Oncocyte Corporation (the "Issuer"), no par value (the "Common Stock"), that were distributed by Halle Special Situations Fund LLC (the "Halle Fund") on a pro rata basis to its members (the "Halle Common Stock Distribution").

F2: Represents shares of Common Stock directly beneficially owned by the Halle Fund. John Peter Gutfreund (the "Reporting Person") is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund.

F3: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities.

F4: Includes 2,004,372 shares of Common Stock received by Newtown Road 130 Holdings LLC ("Newtown") from the Halle Fund as a result of the Halle Common Stock Distribution. The acquisition of the shares of Common Stock by Newtown in the Halle Common Stock Distribution constituted a change in the form of beneficial ownership without a change in pecuniary interest that is exempt from Section 16 of the Exchange Act pursuant to Rule 16a-13 thereunder. Rule 16a-9(a) under the Exchange Act may also exempt the acquisition of the shares of Common Stock by Newtown in the Halle Common Stock Distribution from Section 16 of the Exchange Act.

F5: Represents shares of Common Stock directly beneficially owned by Newtown. The Reporting Person is the managing member and a control person of Newtown. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by Newtown.

F6: Represents shares of Common Stock held by or for the benefit of the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities. In such capacity, the Reporting Person may be deemed to beneficially own any securities held by or for the benefit of the minor children of the Reporting Person.

F7: Includes 10,000 restricted stock units, which will vest on August 15, 2023.

F8: Represents warrants to purchase shares of Common Stock (the "Warrants") that were distributed by the Halle Fund on a pro rata basis to its members (the "Halle Warrant Distribution").

F9: The Warrants are currently exercisable, subject to a beneficial ownership limitation of 4.99%.

F10: Represents Warrants directly beneficially owned by the Halle Fund. The Reporting Person is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund.

F11: Represents Warrants received by Newtown from the Halle Fund as a result of the Halle Warrant Distribution. The acquisition of the Warrants by Newtown in the Halle Warrant Distribution constituted a change in the form of beneficial ownership without a change in pecuniary interest that is exempt from Section 16 of the Exchange Act pursuant to Rule 16a-13 thereunder. Rule 16a-9(a) under the Exchange Act may also exempt the acquisition of the Warrants by Newtown in the Halle Warrant Distribution from Section 16 of the Exchange Act.

F12: Represents Warrants directly beneficially owned by Newtown. The Reporting Person is the managing member and a control person of Newtown. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by Newtown.

F13: The options to purchase shares of Common Stock will vest on August 15, 2023.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2023 Filed Jul 3, 2023 22:00 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	OtherWarrants to Purchase Common Stock · Derivative	3,564,728	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0000899243-23-016837 · doc4.xml · derivative · entry 5 Gutfreund John Peter · CIK 0001940797 · Former Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,001,876 shares Expires 2027-04-19 F8 · shares: Represents warrants to purchase shares of Common Stock (the "Warrants") that were distributed by the Halle Fund on a pro rata basis to its members (the "Halle Warrant Distribution"). F9 · derivative.exercise_date: The Warrants are currently exercisable, subject to a beneficial ownership limitation of 4.99%. F3 · ownership.nature: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities. F10 · ownership.nature: Represents Warrants directly beneficially owned by the Halle Fund. The Reporting Person is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund. Read SEC document
June 30, 2023 Filed Jul 3, 2023 22:00 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	OtherCommon Stock, no par value	3,085,047	$0.00	$0.00	Disclosure SEC source: 0000899243-23-016837 · doc4.xml · nonDerivative · entry 1 Gutfreund John Peter · CIK 0001940797 · Former Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · shares: Represents shares of Common Stock of Oncocyte Corporation (the "Issuer"), no par value (the "Common Stock"), that were distributed by Halle Special Situations Fund LLC (the "Halle Fund") on a pro rata basis to its members (the "Halle Common Stock Distribution"). F2 · ownership.nature: Represents shares of Common Stock directly beneficially owned by the Halle Fund. John Peter Gutfreund (the "Reporting Person") is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund. F3 · ownership.nature: The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities. Read SEC document
April 03, 2023 Filed Apr 6, 2023 01:30 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	Disposition to issuerSeries A Convertible Preferred Stock · Derivative	588.2353	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0001493152-23-011106 · ownership.xml · derivative · entry 3 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, no par value · 384,470 shares Expires 2024-04-08 F2 · derivative.exercise_price: The 588.2353 shares of Series A Convertible Preferred Stock (the "Series A Shares") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the "Purchase Agreement"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended. F2 · shares: The 588.2353 shares of Series A Convertible Preferred Stock (the "Series A Shares") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the "Purchase Agreement"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The 588.2353 shares of Series A Convertible Preferred Stock (the "Series A Shares") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the "Purchase Agreement"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.expiration_date: The 588.2353 shares of Series A Convertible Preferred Stock (the "Series A Shares") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the "Purchase Agreement"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended. F3 · balance_after: The Reporting Person previously misreported on his Form 3 filed with the Securities and Exchange Commission on August 8, 2022 the number of Series A Shares he owned due to an administrative error. As of the date of that Form 3 filing, the Reporting Person owned 588.2353 Series A Shares, not the 1,176.48 Series A Shares reported. Following the disposition of 588.2353 Series A Shares reported here, the Reporting Person does not own any Series A Shares. Read SEC document
April 03, 2023 Filed Apr 6, 2023 01:30 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	GrantCommon Stock, no par value	1,000,000	$0.35	$354,400.00	Disclosure SEC source: 0001493152-23-011106 · ownership.xml · nonDerivative · entry 2 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,075,000 F1 · ownership.nature: These shares of the Issuer's common stock, no par value ("Common Stock"), are held by Newtown Road 130 Holdings LLC ("Newtown"). The Reporting Person is the Managing Member of Newtown and in such capacity has the right to vote and dispose of securities held by Newtown. Read SEC document
April 03, 2023 Filed Apr 6, 2023 01:30 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	GrantCommon Stock, no par value	705,000	$0.35	$249,852.00	Disclosure SEC source: 0001493152-23-011106 · ownership.xml · nonDerivative · entry 1 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,000 Read SEC document
December 23, 2022 Filed Dec 28, 2022 21:05 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	PurchaseCommon Stock, no par value	75,000	$0.33	$24,727.50	Disclosure SEC source: 0001493152-22-036653 · ownership.xml · nonDerivative · entry 1 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 75,000 F1 · price: The price of $0.3297 per share represents a weighted average of prices ranging from $0.31 to $0.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares of common stock are held by Newtown Road 130 Holdings LLC. The Reporting Person is the Managing Member of Newtown Road 130 Holdings LLC and in such capacity has the right to vote and dispose of the securities held by such entity. Read SEC document
August 15, 2022 Filed Aug 18, 2022 00:19 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	GrantOption to Purchase Common Stock · Derivative	45,000	$0.00 Strike: $0.97	$0.00	Disclosure SEC source: 0001493152-22-023380 · ownership.xml · derivative · entry 3 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-08-15 F4 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document
August 15, 2022 Filed Aug 18, 2022 00:19 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	PurchaseCommon Stock, no par value	25,000	$0.93	$23,250.00	Disclosure SEC source: 0001493152-22-023380 · ownership.xml · nonDerivative · entry 2 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,000 F2 · price: The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities. Read SEC document
August 15, 2022 Filed Aug 18, 2022 00:19 UTC	Insight Molecular Diagnostics Inc. OCX · Entity 6631	GrantCommon Stock, no par value	10,000	$0.00	$0.00	Disclosure SEC source: 0001493152-22-023380 · ownership.xml · nonDerivative · entry 1 Gutfreund John Peter · CIK 0001940797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · security: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.